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Background: A plasma glucose value ≥155 mg/dl for 1-hour post-load plasma glucose during an oral glucose
tolerance test (OGTT) is able to identify subjects with normal glucose tolerance (NGT) at high-risk for type-2 diabetes
and with subclinical organ damage. We designed this study to address if 25-hydroxyvitamin D [25(OH)D] circulating
levels are associated with glucose tolerance status, and in particular with 1-hour post-load plasma glucose levels.
Methods: We enrolled 300 consecutive Caucasian hypertensive never-treated outpatients (160 men and 140
women, aged 52.9 ± 9.2 years). Subjects underwent OGTT and measurements of 25(OH)D and standard laboratory
tests. Estimated glomerular filtration rate (e-GFR) was calculated by CKD-EPI formula and insulin sensitivity was
assessed by Matsuda-index.
Results: Among participants, 230 were NGT, 44 had impaired glucose tolerance (IGT) and 26 had type-2 diabetes.
According to 1-h post-load plasma glucose cut-off point of 155 mg/dL, we divided NGT subjects into: NGT < 155
(n = 156) and NGT > 155 mg/dL (n = 74).
NGT≥ 155 had higher significant fasting and post-load glucose and insulin, parathyroid hormone and hs-CRP levels
than NGT < 155. On the contrary, Matsuda-index, e-GFR, and 25(OH)D were significantly lower in NGT≥ 155 than
NGT < 155 subjects. In the multiple regression analysis, 25(OH)D levels resulted the major determinant of 1-h
post-load plasma glucose in all population and in the four groups of glucose tolerance status. In the whole
population, Matsuda-index, hs-CRP and e-GFR explained another 12.2%, 6.7% and 1.7% of its variation.
Conclusions: Our data demonstrate a significant and inverse relationship between 25(OH)D levels and glucose
tolerance status, particularly with 1-h post-load glucose.
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Vitamin D is an important micronutrient involved in
calcium homeostasis, musculoskeletal health and in the
pathophysiology of different organ systems. In fact, vitamin
D receptors have an extensive tissue distribution including
skeletal muscle, vascular smooth cells, cardiomyocytes,
endothelium and pancreatic β-cells [1,2]. Recently, some
experimental and clinical data showed a strong association
between hypovitaminosis D and different clinical condi-
tions, suggesting the hypothesis that vitamin D deficiency* Correspondence: perticone@unicz.it
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unless otherwise stated.plays a crucial role in the pathogenesis of both metabolic
and cardiovascular diseases [3-6].
Growing evidences, but not all, indicate that subopti-
mal vitamin D status plays a role in the development of
impaired glucose homeostasis, insulin resistance and
type-2 diabetes [7-14] because it causes impairment in
insulin receptor expression and insulin secretion in ani-
mal models and humans [15,16]. In particular, in a large
sample from the Ely study, baseline 25-hydroxyvitamin
D [25(OH)D] levels were inversely associated with 10-
year risk of hyperglycemia, insulin-resistance and meta-
bolic syndrome [7]. Moreover, higher plasma 25(OH)D
concentrations are associated with lower risk of incident
type-2 diabetes in women, in a case–control retrospect-
ive analysis conducted in a large sample of the Nurses’al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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onstrating no association between vitamin D levels and
glucose tolerance status in the general population [17]
and in the obese subjects [18].
Recently, a cut-off point of 155 mg/dL for 1-h post-load
plasma glucose value during the oral glucose tolerance test
(OGTT) was able to identify subjects with normal glucose
tolerance (NGT) but at high risk of type-2 diabetes [19].
In addition, in hypertensive patients, the 1-h post-load
plasma glucose value was strongly associated with differ-
ent subclinical organ damage [20-24] thus increasing risk
for future cardiovascular events [25-27].
However, at this moment it is unknown whether vita-
min D levels are able to affect 1-h post-load plasma glu-
cose in hypertensive NGT subjects. Thus, we designed
this study to evaluate, in a group of newly diagnosed
hypertensive subjects, the possible relationship between
25(OH)D levels and post-load plasma glucose.
Methods
Study population
To conduct a cross-sectional analysis, we enrolled, dur-
ing the spring, 300 consecutive hypertensive never-treated
outpatients who were free of complications (160 men and
140 women, aged 52.9 ± 9.2 years, age range 36–58 years)
and participating in the Catanzaro Metabolic Risk Factors
Study (CATAMERIS). All subjects were Caucasian and
underwent physical examination and review of their
medical history with regard to family history of diabetes.
Secondary forms of hypertension were excluded by sys-
tematic testing by a standard clinical protocol, including
renal U.S. studies, computed tomography, renal scan,
catecholamine, plasma renin activity, and aldosterone
measurements. Other exclusion criteria were history or
clinical evidence of coronary and/or valvular heart disease,
congestive heart failure, hyperlipidaemia, peripheral vas-
cular disease, chronic gastrointestinal diseases associated
with malabsorption, or chronic pancreatitis; history of
malignant disease, alcohol or drug abuse, or liver or kid-
ney failure; and any treatments interfering with glucose or
vitamin D metabolism.
All subjects underwent evaluation for weight, height,
and body mass index (BMI). After 12-h fasting, a 75-g
OGTT was performed with 0, 30, 60, 90, and 120-min
sampling for plasma glucose and insulin. Briefly, the
test was performed using a glucose load containing
the equivalent of 75 g anhydrous glucose dissolved in
water. Glucose tolerance status was defined on the basis
of OGTT using the World Health Organization criteria.
In particular, T2D was defined by a 2-h plasma glucose ≥
200 mg/dL (11.1 mmol/L), whereas patients with a 2-h
plasma glucose between 140 mg/dL (7.8 mmol/L) to
199 mg/dL (11.0 mmol/L) were considered IGT [28].
Insulin sensitivity was evaluated using the Matsudaindex (insulin sensitivity index [ISI]), calculated as
10,000/square root of [fasting glucose (mmol/L) ×
fasting insulin (mU/L)] × [mean glucose × mean insulin
during OGTT]. The Matsuda index is strongly related to
the euglycemic hyperinsulinemic clamp, which represents
the gold standard test for measuring insulin sensitivity [29].
The ethical committee approved the protocol, and in-
formed written consent was obtained from all participants.
All the investigations were performed in accordance with
the principles of the Declaration of Helsinki.
Blood pressure measurements
Readings of clinic blood pressure (BP) were measured at
3-minute intervals using a standard sphygmomanometer,
and BP values were the average of 3 measurements after
a 10-minute period of rest in the supine position. This
evaluation was repeated on three separate occasions at
least 2 weeks apart. Patients with a clinic systolic BP
(SBP) >140 mmHg and/or diastolic BP (DBP) >90 mmHg
were defined as hypertensive.
Laboratory determinations
All laboratory measurements were performed after a fast
of at least 12 h. Plasma glucose was determined immedi-
ately by the glucose oxidase method (Glucose Analyzer,
Beckman Coulter S.p.A.,Milan, Italy). Triglyceride and
total, low-density lipoprotein (LDL), and high-density
lipoprotein (HDL) cholesterol concentrations were mea-
sured by enzymatic methods (Roche Diagnostics GmbH,
Mannheim, Germany). Plasma concentrations of insulin
and intact parathyroid hormone were determined by
chemiluminescence test (Roche Diagnostics). Serum cre-
atinine was measured in the routine laboratory by an au-
tomated technique based on the measurement of Jaffe
chromogenic assay. C-reactive protein (CRP) was mea-
sured by a high-sensitivity turbidimetric immunoassay
(Behring, Marburg, Germany). Values of estimated glom-
erular filtration rate (e-GFR; mL/min/1.73 m2) were calcu-
lated by using the new equation proposed by investigators
in the Chronic Kidney Disease Epidemiology (CKD-EPI)
Collaboration [30].
Plasma levels of 25(OH)D were measured by competitive
immunoassay with chemiluminescence (CLIA) through
the Liaison-Diasorin test, in all patients. Venous samples
for the determination of 25(OH)D have been carried out in
the morning, on fasting condition. A sample of 2.5 ml of
venous blood was collected, and subsequently introduced
into disposable test tube equipped with separation acceler-
ator granules. The blood sample was centrifuged for
5 minutes at 2500 rpm in a special centrifuge, 500 μl of
the obtained serum were collected and placed in special
cuvettes. During the first incubation, the 25(OH)D was
dissociated from its binding protein and it was tied to the
specific antibody. After 10 minutes, a tracer consisting of
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nutes, subsequently the unbound material was removed
with a wash cycle. In the last step, the reagents for the
chemiluminescence reaction were added. Finally, the sig-
nal was measured by a photomultiplier as relative light
units (RLU) and it was inversely correlated with the 25
(OH)D concentration in each sample. Vitamin D status
was classified as follows: deficient (<20 ng/ml), insufficient
(20 to <30 ng/ml) and normal (≥30 ng/ml).
Statistical analysis
Normally distributed data were summarized as mean ±
SD, while not normally distributed data as median and
interquartile range. Variables having a positively skewed
distribution were log transformed (lg10) before the correl-
ational analysis. Considering normally distributed data,
ANOVA for clinical and biologic data was performed to
test the differences among groups, and the BonferroniTable 1 Anthropometric, hemodynamic and biochemical char
tolerance status
All NGT < 155
Variables (n = 300) (n = 156)
Gender, m/f 160/140 74/82
Age, years 52.9 ± 9.2 52.9 ± 8.7
Waist, cm 91.6 ± 9.1 89.5 ± 7.4
BMI, Kg/m2 28.1 ± 4.2 27.3 ± 4.0
SBP, mmHg 141.8 ± 10.7 140.9 ± 8.5
DBP, mmHg 91.3 ± 6.9 91.4 ± 6.3
Fasting glucose, mg/dl 94.8 ± 11.5 90.1 ± 7.2
1-h glucose, mg/dl 152.3 ± 48.4 116.1 ± 24.0
2-h glucose, mg/dl 124.7 ± 38.3 105.2 ± 17.6
Fasting insulin, μU/ml 13.5 ± 7.1 11.3 ± 5.4
1-h insulin, μU/ml 111.6 ± 62.1 91.2 ± 54.7
2-h insulin, μU/ml 85.0 ± 56.1 61.8 ± 45.9
MATSUDA/ISI 66.5 ± 37.3 83.5 ± 40.8
Total cholesterol, mg/dl 212.5 ± 37.4 211.8 ± 36.7
HDL-cholesterol, mg/dl 49.6 ± 12.5 51.9 ± 12.3
Triglyceride, mg/dl 122.1 ± 47.6 115.7 ± 40.3
hs-CRP, mg/l 2.5 ± 1.9 1.8 ± 1.1
Creatinine, mg/dl 0.8 ± 0.2 0.8 ± 0.1
e-GFR, ml/min/1.73 m2 100.1 ± 25.1 104.1 ± 22.9
25(OH)D, ng/ml 23.5(18–32.9) 26.5(20–35.6)
Parathyroid hormone, pg/ml 62.7 ± 42.7 50.7 ± 37.5
Calcium, mg/dl 9.4 ± 0.5 9.4 ± 0.3
Phosphorus, mg/dl 3.3 ± 0.4 3.3 ± 0.4
Current smokers, n(%) 80(26.7) 45(28.8)
*By ANOVA; **By χ2 test; § by Kruskal Wallis test.
NGT = normal glucose tolerance; IGT = impaired glucose tolerance; DM = diabetes m
blood pressure; ISI = insulin sensitivity index; hs-CRP = high sensitivity C-reactive propost-hoc test for multiple comparisons was further per-
formed as requested. In addition, Kruskal Wallis test was
used to compare the medians among the different groups
for not normally distributed data. The χ2 test was used
for categorical variables. The Pearson method was used to
calculate the relationship between 1-h post-load glucose
and the following covariates: age, BMI, blood pressure,
total and HDL-cholesterol, triglyceride, Matsuda index,
high-sensitivity CRP (hs-CRP), e-GFR and 25(OH)D. Vari-
ables reaching statistical significance, gender and smoking,
as dichotomous values, were inserted in a stepwise multi-
variate linear regression model to determine the inde-
pendent predictors of 1-h post-load plasma glucose. The
analysis was performed for whole study population and
according to different groups of glucose tolerance. Differ-
ences were assumed to be significant at P < 0.05. All com-
parisons were performed using SPSS 20.0 statistical
software (SPSS, Inc., Chicago, IL).acteristics of the study population according to glucose
NGT ≥ 155 IGT DM P*
(n = 74) (n = 44) (n = 26)
44/30 26/18 16/10 0.274**
52.7 ± 10.9 53.3 ± 9.4 53.3 ± 7.2 0.984
93.5 ± 9.5 94.1 ± 11.6 94.7 ± 9.7 <0.0001
28.4 ± 4.2 28.8 ± 4.6 29.3 ± 3.9 0.028
142.4 ± 12.6 143.2 ± 12.8 143.1 ± 12.1 0.463
91.5 ± 7.3 90.8 ± 7.8 91.4 ± 8.1 0.956
98.6 ± 15.6 99.7 ± 8.3 103.8 ± 11.6 <0.0001
182.6 ± 26.2 188.7 ± 39.3 221.6 ± 38.9 <0.0001
114.1 ± 18.6 155.6 ± 11.8 220.2 ± 21.7 <0.0001
15.3 ± 7.3 16.3 ± 7.9 16.7 ± 8.9 <0.0001
151.8 ± 61.7 115.9 ± 63.1 109.7 ± 50.8 <0.0001
97.9 ± 60.3 117.3 ± 57.5 113.1 ± 41.6 <0.0001
52.4 ± 25.4 50.5 ± 22.8 44.1 ± 22.5 <0.0001
212.2 ± 40.5 213.6 ± 39.2 215.5 ± 29.6 0.968
47.2 ± 10.9 47.7 ± 14.4 45.6 ± 12.1 <0.0001
128.4 ± 50.4 129.1 ± 49.8 131.5 ± 69.3 0.106
3.2 ± 2.1 3.3 ± 2.4 3.7 ± 2.1 <0.0001
0.9 ± 0.2 0.9 ± 0.2 0.9 ± 0.3 <0.0001
96.7 ± 24.6 95.8 ± 29.2 92.4 ± 28.1 0.027
21(16–30) 21.5(15.6-28.7) 18.6(13–24.6) 0.002§
71.6 ± 46.5 77.1 ± 49.9 82.3 ± 19.1 0.004
9.5 ± 0.4 9.3 ± 0.9 9.4 ± 0.4 0.305
3.3 ± 0.3 3.3 ± 0.5 3.1 ± 0.4 0.467
15(20.3) 13(29.5) 7(26.9) 0.750**
ellitus; BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic
tein; e-GFR = estimated glomerular filtration rate.
Figure 1 Vitamin D status according to different groups of
glucose tolerance. In the figure, the vitamin D status, according to
different groups of glucose tolerance, is represented. Of interest,
vitamin D sufficiency significantly decreases from normal glucose
tolerant subjects with 1-hour post-load plasma glucose <155 mg/dl
(NGT < 155) to NGT≥ 155 subjects, impaired glucose tolerant (IGT)
subjects and type-2 diabetic (T2D) patients (P < 0.0001). On the
contrary the prevalence of vitamin D deficiency significantly
increases from the first to the fourth group (P < 0.0001).
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Study population
Of 300 patients examined by OGTT, 230 (76.7%) were
NGT, 44 (14.7%) had impaired glucose tolerance (IGT)
and 26 (8.6%) had newly diagnosed type-2 diabetes. A 1-
h post-load plasma glucose cut-off of 155 mg/dL during
the OGTT was used to stratify NGT subjects into two
groups: 156 with 1-h post-load plasma glucose <155 mg/dL
(NGT < 155) and 74 with 1-h post-load plasma glucose
> 155 mg/dL (NGT ≥ 155). In Table 1 demographic,
clinical, and biochemical characteristics of the study
groups are reported. There were no significant differences
among the groups in gender distribution, age, SBP, DBP,
total cholesterol and triglyceride, serum calcium and
phosphorus. On the contrary, from the NGT < 155 to the
diabetic patients, there was a significant increase in waist
circumference, BMI, hs-CRP, creatinine, and a decrease in
HDL cholesterol and e-GFR. Obviously, with the worsen-
ing of glucose tolerance, there was a progressive increase
of fasting, 1-h and 2-h post-load glucose, as well as fasting
and 1-h and 2-h insulin values, accounting for the reduc-
tion of the Matsuda index/ISI.
Moreover, from the NGT < 155 to the diabetic patients
there was a progressive decrease of 25(OH)D and an in-
crease of parathyroid hormone levels. Of interest, NGT
≥ 155 subjects had significantly reduced insulin sensitiv-
ity and 25(OH)D levels, and an increase of hs-CRP values
when compared with NGT < 155; in addition, they had a
metabolic and inflammatory profiles similar to IGT and
diabetic individuals.
In whole population, 104 (34.7%) patients had a defi-
cient vitamin D status, 104 patients (34.7%) had an in-
sufficient vitamin D status and 92 patients (30.6%) had a
normal vitamin D status.
Subjects with vitamin D sufficiency significantly de-
creased from NGT < 155 subjects to diabetic patients (P <
0.0001), while the prevalence of vitamin D deficiency in-
creased from the NGT < 155 to the diabetic patients (P <
0.0001), reaching a 69.2% in the last (Figure 1).
Correlational analysis
In Table 2 the results of linear correlation analysis, performed
to test the correlation between 1-h post-load glucose and dif-
ferent covariates, are reported. In the whole study popula-
tion, 1-h post-load glucose was inversely correlated with
25(OH)D, Matsuda index, e-GFR and HDL-cholesterol,
and it was directly correlated with hs-CRP, BMI and age.
In NGT < 155 subjects, 1-h post-load glucose was
directly related with age, and inversely with 25(OH)D,
Matsuda index and e-GFR.
The same analysis was performed in NGT ≥ 155 sub-
jects showing that 1-h post-load glucose was inversely
correlated with 25(OH)D, Matsuda index and e-GFR,
while was linearly correlated with age and hs-CRP.Similarly, in IGT patients 1-h post-load glucose was
inversely correlated with 25(OH)D and e-GFR and it was
linearly correlated with BMI, moreover it showed a weak
correlation with age.
Finally, diabetic patients showed an inverse correlation
between 1-h post-load glucose and 25(OH)D and e-GFR;
while it was directly correlated with hs-CRP.
Thus, variables reaching statistical significance and
gender, as a dichotomous value, were inserted in a step-
wise multivariate linear regression model to determine
the independent predictors of 1-h post-load glucose vari-
ation (Table 3). In the whole study population, 25(OH)D
was the major predictor of 1-h post-load glucose, explain-
ing 19.2% of its variation. Other independent predictors
were the Matsuda index, hs-CRP and e-GFR explaining
12.2%, 6.7% and 1.7% of its variation, respectively.
In NGT < 155 subjects, the covariates retained in the
final model were 25(OH)D, the Matsuda index and age
which explained 12%, 18% and 4% of the 1-h post-load
plasma glucose variation, respectively. The final model
accounted for 34% of its variation.
In NGT ≥ 155 and IGT patients, 25(OH)D was the
strongest predictor of 1-h post-load glucose, justifying for
28.1% and 27% of its variation in the respective models.
Age in NGT ≥ 155 subjects and BMI in IGT patients
added another 5.8% and 8.4% of 1-h post load glucose
variation. The final model accounted for 33.9% and 35.4%
of 1-h post load glucose variation, respectively.
Table 2 Correlation analysis between 1-h post load plasma glucose and different covariates in whole study population
and in the four groups of different glucose tolerance status
All NGT < 155 NGT ≥ 155 IGT DM
(n = 300) (n = 156) (n = 74) (n = 44) (n = 26)
r P r P R P r P r P
25(OH)D, ng/ml - 0.439 <0.0001 −0.404 <0.0001 -0.541 <0.0001 −0.480 <0.0001 −0.590 0.004
Matsuda index/ISI −0.418 <0.0001 −0.265 <0.0001 −0.208 0.037 −0.170 0.134 −0.014 0.472
hsCRP, mg/dl 0.384 <0.0001 0.016 0.422 0.240 0.020 0.032 0.418 0.342 0.043
e-GFR, ml/min/1.73 m2 −0.295 <0.0001 −0.209 0.004 −0.282 0.007 −0.307 0.021 −0.347 0.041
BMI, Kg/m2 0.188 0.001 0.006 0.471 −0.005 0.484 0.378 0.006 −0.036 0.430
Age, years 0.187 0.001 0.424 <0.0001 0.364 0.001 0.256 0.047 −0.212 0.149
HDL-cholesterol mg/dl - 0.170 0.002 −0.114 0.078 −0.095 0.209 0.216 −0.080 0.007 0.487
SBP, mmHg 0.097 0.056 0.069 0.197 0.047 0.345 0.048 0.378 0.040 0.423
Triglyceride, mg/dl 0.084 0.073 0.002 0.492 0.113 0.169 0.028 0.427 0.185 0.183
DBP, mmHg −0.030 0.303 0.010 0.453 −0.072 0.270 0.112 0.235 0.062 0.381
Total cholesterol mg/dl 0.028 0.312 0.018 0.410 −0.020 0.432 0.026 0.433 0.082 0.345
ISI = insulin sensitivity index; hs-CRP = high sensitivity C reactive protein; e-GFR = estimated glomerular filtration rate; BMI = body mass index; SBP = systolic blood
pressure; DBP = diastolic blood pressure.
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dependent predictor of 1-h post load glucose justifying
25.4% of 1-h post load plasma glucose variation.
Discussion
The main novelty obtained in this study is that, in a
large population of newly diagnosed hypertensive pa-
tients, with different glucose tolerance status, there is an
inverse and strong relationship between 25(OH)D levels
and 1-h post-load glucose in normo-glycemic subjects. In
fact, regarding to post-load plasma glucose, NGT ≥ 155
subjects showed reduced 25(OH)D levels compared to
NGT < 155 and similar to those of IGT group. Of interest,
this result persists after adjustment for all significant co-
variates, able to interfere with glycemic metabolism. To
our knowledge, this is the first study demonstrating this
association that has a clinical importance because NGT






Partial R2 (%) P Partial R2 (%) P
25(OH)D, ng/ml 19.2 <0.0001 12.0 <0.0001
Matsuda index/ISI 12.2 <0.0001 18.0 <0.0001
hs-CRP, mg/L 6.7 <0.0001 – –
e-GFR, ml/min/1.73 m2 1.7 0.005 – –
Age, years – – 4.0 0.003
BMI, Kg/m2 – – – –
Total R2 (%) 39.8 – 34.0 –
hs-CRP = high sensitivity C reactive protein; ISI = insulin sensitivity index; e-GFR = escontrary, we have recently demonstrated that NGT with
1-h post-load glucose ≥155 have a worse metabolic and
cardiovascular profile, showing a multiple subclinical organ
damage [20-24]. Thus, our data consent to reconsider the
concept that NGT subjects are a homogeneous group with
a low cardiovascular and metabolic risk profile.
Present results may be explained by the pathophysio-
logical mechanisms related to pleiotropic action of vita-
min D. In particular, vitamin D may affect both directly,
via activation of vitamin D receptors, and indirectly, via
regulation of calcium availability, glucose and insulin
homeostasis by modulating β-cell function and immune
response, and improving peripheral insulin sensitivity
[1,2,15]. In keeping with this, there are experimental
data demonstrating that hypovitaminosis D causes im-
pairment in insulin receptor expression and insulin se-
cretion in animal models and humans [15,16], while







Partial R2 (%) P Partial R2 (%) P Partial R2 (%) P
28.1 <0.0001 27.0 0.0001 25.4 0.009
– – – – – –
– – – – – –
– – – – – –
5.8 0.015
– – 8.4 0.026 – –
33.9 – 35.4 – 25.4 –
timated glomerular filtration rate; BMI = body mass index.
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glucose metabolism, low levels of vitamin D are associated
to the apperance and progression of pro-inflammatory
status that, in turn, induces a worsening of glucose toler-
ance status until the clinical onset of diabetes [33,34].
According with this, NGT ≥155 subjects, both in basal
condition and after 1-hour during OGTT, are more
insulin-resistant and have higher levels of hs-CRP than
NGT < 155. On the basis of these evidences, present data
contribute to extend previous knowledge about the associ-
ation between hypovitaminosis D and cardiovascular
events [3-6]. Additional mechanism involved in this asso-
ciation is the regulatory effect of vitamin D on the renin-
angiotensin system activity. In fact, there are previously
published human and animal studies demonstrating that
low plasma vitamin D levels result in up-regulation of the
renin-angiotensin system [16,35] that interferes with insu-
lin signaling in different tissues [36-38].
Even if data from several studies have demonstrated
that circulating levels of vitamin D are involved in the
pathogenesis of type-2 diabetes in humans [7-15], it is
probable that other associated functional modifications
or clinical conditions contribute to its biological effects.
So as observed in our study, vitamin D deficiency is
also associated with elevated PTH levels that repro-
duce a secondary hyperparathyroidism that may contrib-
ute, through the reduction of insulin sensitivity and by
promoting cardiac and vascular remodeling, to the devel-
opment of glucose intolerance and cardiovascular compli-
cations [39]. Of interest, present data were obtained in
subjects with normal renal function. In addition, reduced
levels of vitamin D may be operating in diabetes-related
obesity; in fact, hypovitaminosis D of obese subjects is
due, not only to less exposure to sunlight for the reduction
of physical activity, but also because vitamin D is trapped
in adipose tissue and it is no longer bioavailable [40,41]. It
follows that the biological action of vitamin D is multifac-
torial and complex, especially as regards to the glucose
metabolism. In keeping with this, recently some study
have been published with the aim to evaluate the effects of
vitamin D supplementation on glucose metabolism and
insulin resistance in different setting of patients [42-46].
However, despite the significant increase of vitamin D
levels, the absence of consistent results may be explained
with the short duration of treatment.
Another important finding emerged from this study is
that the number of subjects with sufficient vitamin D
levels is low and significantly decreases with the worsen-
ing of tolerance status, while the condition of vitamin D
deficiency significantly increases. This is a surprise not
easily explained, since all our patients live in a sunny
area of South Italy and spend many hours outdoors,
maybe the season period of study may affect the levels.
On the other hand, average levels of vitamin D detectedin our subjects are similar to the national average; prob-
ably, it is necessary to accurately investigate the causes
of this phenomenon.
Conclusions
Present study might suggest new pathogenetic mecha-
nisms involved in glucose metabolism in particular on
post-load glucose, and might contribute to early stratify
the cardiovascular and metabolic risk profile at least in
hypertensive patients. In particular, our data demon-
strate, for the first time, that vitamin D levels are signifi-
cantly associated with post-load glucose in hypertensive
normo-glycemic subjects. Thus, according to previous
published evidences, it can be hypothesized that vitamin
D deficiency should not be considered only as a feature
of osteo-mineral disorders, but also a risk factor for
metabolic and cardiovascular diseases. However, if vita-
min D supplementation may have a beneficial role on
insulin-resistance and glucose homeostasis is currently
controversial as shown by a recent meta-analysis of ran-
domized controlled trials, that reported no significant
improvement of fasting glucose, glycated haemoglobin
or insulin resistance in patients treated with 25(OH)D
compared with placebo [47]. Thus, it should be neces-
sary to perform a larger randomized prospective study
to clarify this point.
Limitations of the study
This study has several limitations. At first, this is a cross-
sectional study, thus cause-effect relationships cannot be
established; moreover the study was conducted in a spe-
cific cohort of untreated hypertensive patients, which may
be not representative of general population. Finally, the
study doesn’t take into account some covariates influen-
cing 25(OH)D levels, so as physical activity and social
class.
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